Showing results 15 to 30 of 30
< previous
| Issue Date | Title | Author(s) |
| 4-Nov-2021 | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China | Liu, Weiping; Zhao, Donglu; Liu, Ting; Niu, Ting; Song, Yongping; Xu, Wei; Jin, Jie; Cai, Qingqing; Huang, Huiqiang; Li, Zhiming; Hou, Ming; Zhang, Huilai; Zhou, Jianfeng; Hu, Jianda; Shen, Jianzhen; Shi, Yuankai; Yang, Yu; Zhang, Liling; Zhao, Weili; Ding, Kaiyang; Qiu, Lugui; Tan, Huo; Zhang, Zhihui; Liu, Lihong; Wang, Jinghua; Xu, Bing; Zhou, Hui; Gao, Guangxun; Xue, Hongwei; Bai, Ou; Feng, Ru; Huang, Xiaobing; Yang, Haiyan; Yan, Xiaojing; Zeng, Qingshu; Liu, Peng; Li, Wenyu; Mao, Min; Su, Hang; Wang, Xin; Xu, Jingyan; Zhou, Daobin; Zhang, Hongyu; Ma, Jun; Shen, Zhixiang; Zhu, Jun |
| 2-Nov-2023 | A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas | Song, Yuqin; Li, Zengjun; Wu, Huijing; Jin, Jie; Zhou, Hui; Zhou, Keshu; Zhang, Liling; Peng, Zhigang; Zhang, Zhiye; Cen, Hong; Jia, Youchao; Shuang, Yuerong; Li, Zhiming; Yang, Haiyan; Zou, Liqun; Li, Zhifeng; Zhang, Zhihui; Li, Junmin; Cao, Junning; Qiu, Lugui; Wu, Shaojie; Gong, Tiejun; Xu, Xiaohong; Wang, Zhen; Zhu, Jun |
| 2014 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma | Geng, Chuanying; Hou, Jian; Zhao, Yaozhong; Ke, Xiaoyan; Wang, Zhao; Qiu, Lugui; Xi, Hao; Wang, Fuxu; Wei, Na; Liu, Yan; Yang, Shifang; Wei, Peng; Zheng, Xiangjun; Huang, Zhongxia; Zhu, Bing; Chen, Wen-Ming |
| 2007 | An open-label study of pegylated liposomal doxorubicin, vincristine and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in Chinese population | Shen, Yang; Shen, Zhixiang; Jiang, Bin; Hou, Jian; Zhan, Rong; Qiu, Lugui; Wu, Yongji; Jin, Jie; Li, Juan; Meng, Fanyi; Zou, Ping; Liu, Ting; Li, Jianyong; Wang, Chun; Wu, Depai; Ma, Jun |
| 15-Apr-2023 | The Oral PI3Kd Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial | Wang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Su, Hang; Cao, Junning; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jin, Jie; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 15-Jul-2020 | Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study | Jiang, Bo; Ke, Xiaoyan; Zhang, Qingyuan; Xu, Wei; Su, Hang; Huang, Jie; Zhang, Mingzhi; Wang, Huaqing; Jin, Chuan; Zhu, Jun; Liu, Li; Cai, Zhen; Zhao, Xielan; Zhou, Jianfeng; Zhang, Xiaohong; Liu, Jing; Zhou, Hui; Yu, Jie; Sun, Xing; Qi, Junyuan; Qiu, Lugui |
| 23-Aug-2021 | Phase 1 clinical trial of the PI3K delta inhibitor YY-20394 in patients with B-cell hematological malignancies | Jiang, Bo; Qi, Junyuan; Song, Yuqin; Li, Zengjun; Tu, Meifeng; Ping, Lingyan; Liu, Zongliang; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 2019 | A phase I study of a selective PI3K delta inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies. | Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Jiang, Bo; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Zhu, Jun; Xu, Yuanyuan; Bao, Hanying; Xu, Zusheng |
| Jul-2024 | Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors | Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2015 | Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma | Shi, Yuankai; Dong, Mei; Zhu, Jun; Zhou, Daobin; Huang, Huiqiang; Tu, Ping; Zhang, Weijing; Hong, Xiaonan; Zhao, Xielan; Sun, Jianfang; Liu, Yuehua; Qiu, Lugui; Shen, ZhiXiang; Feng, Jifeng; Ke, Xiaoyan |
| 2018 | Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas | Zhu, Jun; Cao, Junning; Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Tu, Meifeng; Ji, Dongmei; Shen, Weina; Sun, Mingyuan; Hua, Ye; Yang, Chen; Yu, Chen; Wang, Jian; Dai, Guangxiu; Su, Weiguo |
| 2018 | Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies | Qi, Junyuan; Song, Yuqin; Jiang, Bo; Li, Jianyong; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Xu, Wei; Zhu, Huayuan; Zhu, Jun; Bao, Hanying; Xu, Zusheng; Qiu, Lugui |
| 2014 | Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma | Chen, Wenming; Wei, Peng; Yang, Shifang; Zheng, Xiangjun; Qiu, Lugui; Hou, Jian; Zhang, Xuejun; Wang, Zhao; Ke, Xiaoyan; Pan, Ling; Pang, Hongyan |
| Apr-2022 | A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies | Song, Yuqin; Sun, Mingyuan; Qi, Junyuan; Xu, Wei; Zhou, Jianfeng; Li, Dengju; Li, Jianyong; Qiu, Lugui; Du, Chenmu; Guo, Haiyi; Huang, Jane; Tang, Zhiyu; Ou, Ying; Wu, Binghao; Yu, Yiling; Zhu, Jun |
| Jul-2022 | Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies | Xu, Wei; Yang, Shenmiao; Tam, Constantine S.; Seymour, John F.; Zhou, Keshu; Opat, Stephen; Qiu, Lugui; Sun, Mingyuan; Wang, Tingyu; Trotman, Judith; Pan, Ling; Gao, Sujun; Zhou, Jianfeng; Zhou, Daobin; Zhu, Jun; Song, Yuqin; Hu, Jianda; Feng, Ru; Huang, Haiwen; Su, Dan; Shi, Miao; Li, Jianyong |
